arenesp

Oppenheimer has published a research report on Amgen Inc. (NASDAQ: AMGN) following an FDA panel discussion on the potential restriction of Arenesp based on safety findings. In the report, Oppenheimer writes "As we had expected, the panel voted against removing Aranesp's indication for treatment of...